Skystar to File Financial Results for Third Quarter of Fiscal 2013 on Thursday, November 14, 2013

Skystar to File Financial Results for Third Quarter of Fiscal 2013 on Thursday, 
November 14, 2013 
Conference Call to follow Friday, November 15, 2013 at 7:45 AM (ET) 
XI'AN, CHINA -- (Marketwired) -- 11/14/13 --   Skystar
Bio-Pharmaceutical Company (NASDAQ: SKBI) ("Skystar" or the
"Company"), a China-based manufacturer and distributor of veterinary
medicines, vaccines, micro-organisms and feed additives, will file
its financial results for the third quarter of fiscal 2013 on
Thursday November 14, 2013 by close of the business day. 
Conference Call Information
 The Company will host a conference call
the next morning Friday, November 15, 2013 to discuss its third
quarter financial results. Skystar's conference call will begin
promptly at 7:45 a.m. ET. Mr. Weibing Lu, Skystar's Chairman and
Chief Executive Officer, will host the call, which will be webcast
live.  
Webcast
 The webcast will be made available at:
http://www.investorcalendar.com/IC/CEPage.asp?ID=171912. 
Phone dial-in
 Telephone access to the conference call will be
available in North America by dialing +1 (877) 407-8031 or
internationally by dialing +1 (201) 689-8031.  
An audio replay of the conference call will be available
approximately two hours following the conclusion of the call and for
the following 30 day period. To access the replay in North America,
dial +1 (877) 660-6853 or, when calling internationally, dial +1
(201) 612-7415, referencing conference ID # 13572867. Alternatively
you can listen to the replay online at
http://www.investorcalendar.com. 
To be added to the Company's email distribution for future news
releases, please send your request to skystar@grayling.com. 
About Skystar Bio-Pharmaceutical Company
 Skystar is a China-based
developer and distributor of veterinary healthcare and medical care
products. Skystar has four product lines (veterinary medicines,
micro-organisms, vaccines and feed additives) and over 284 products.
Skystar has formed strategic sales distribution networks covering 29
provinces throughout China. For additional information, please visit
http://www.skystarbio-pharmaceutical.com. 
Safe Harbor Statement under the Private Securities Litigation Reform
Act of 1995 
 Safe Harbor Statement under the Private Securities
Litigatio
n Reform Act of 1995: Certain of the statements made in the
press release constitute forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
These statements can be identified by the use of forward-looking
terminology such as "believe," "expect," "may," "will," "should,"
"project," "plan," "seek," "intend," or "anticipate" or the negative
thereof or comparable terminology. Such statements typically involve
risks and uncertainties and may include financial projections or
information regarding the progress of new product development. Actual
results could differ materially from the expectations reflected in
such forward-looking statements as a result of a variety of factors,
including the risks associated with the effect of changing economic
conditions in The People's Republic of China, variations in cash
flow, reliance on collaborative retail partners and on new product
development, variations in new product development, risks associated
with rapid technological change, and the potential of introduced or
undetected flaws and defects in products, and other risk factors
detailed in reports filed with the Securities and Exchange Commission
from time to time. 
Contacts: 
Skystar Bio-Pharmaceutical Company
Scott Cramer
Director and U.S. Representative
(407) 645-4433 
Grayling 
Investor Relations
Christopher Chu 
(646) 284-9426
christopher.chu@grayling.com